Local control and patterns of failure for "Radioresistant" spinal metastases following stereotactic body radiotherapy compared to a "Radiosensitive" reference.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 27 11 2020
accepted: 30 12 2020
pubmed: 17 1 2021
medline: 3 11 2021
entrez: 16 1 2021
Statut: ppublish

Résumé

The concept of a radioresistant (RR) phenotype has been challenged with use of stereotactic body radiotherapy (SBRT). We compared outcomes following SBRT to RR spinal metastases to a radiosensitive cohort. Renal cell, melanoma, sarcoma, gastro-intestinal, and thyroid spinal metastases were identified as RR and prostate cancer (PCA) as radiosensitive. The primary endpoint was MRI-based local failure (LF). Secondary endpoints included overall survival (OS) and vertebral compression fracture (VCF). From a prospectively maintained database of 1394 spinal segments in 605 patients treated with spine SBRT, 173 patients/395 RR spinal segments were compared to 94 patients/185 PCA segments. Most received 24-28 Gy in 2 fractions (68.9%) and median follow-up was 15.5 months (range, 1.4-84.2 months). 1- and 2-year LF rates were 19.2% and 22.4% for RR metastases, respectively, which were significantly greater (p < 0.001) than PCA (3.2% and 8.4%, respectively). Epidural disease (HR: 2.47, 95% CI 1.65-3.71, p < 0.001) and RR histology (HR: 2.41, 95% CI 1.45-3.99, p < 0.001) predicted for greater LF. Median OS was 17.4 and 61.0 months for RR and PCA cohorts, respectively. Lung/liver metastases, polymetastatic disease and epidural disease predicted for worse OS. 2-year VCF rates were ~ 13% in both cohorts. Coverage of the CTV V90 (clinical target volume receiving 90% of prescription dose) by ≥ 87% (HR: 2.32, 95% CI 1.29-4.18, p = 0.005), no prior spine radiotherapy (HR: 1.96, 95% CI 1.09-3.55, p = 0.025), and a greater Spinal Instability Neoplasia Score (p = 0.013) predicted for VCF. Higher rates of LF were observed after spine SBRT in RR metastases. Optimization strategies include dose escalation and aggressive management of epidural disease.

Identifiants

pubmed: 33453002
doi: 10.1007/s11060-020-03691-6
pii: 10.1007/s11060-020-03691-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-182

Références

Harel R, Angelov L (2010) Spine metastases: current treatments and future directions. Eur J Cancer 46(15):2696–2707. https://doi.org/10.1016/j.ejca.2010.04.025
doi: 10.1016/j.ejca.2010.04.025 pubmed: 20627705
Lutz S, Balboni T, Jones J et al (2016) Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 7(1):4–12. https://doi.org/10.1016/j.prro.2016.08.001
doi: 10.1016/j.prro.2016.08.001 pubmed: 27663933
Husain ZA, Sahgal A, Salles AD et al (2017) Stereotactic body radiotherapy for de novo spinal metastases: systematic review: International Stereotactic Radiosurgery Society practice guidelines. J Neurosurg Spine 27(3):295–302. https://doi.org/10.3171/2017.1.SPINE16684
doi: 10.3171/2017.1.SPINE16684 pubmed: 28598293
Sahgal A, Larson DA, Chang EL (2008) Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 71(3):652–665. https://doi.org/10.1016/j.ijrobp.2008.02.060
doi: 10.1016/j.ijrobp.2008.02.060 pubmed: 18514775
Hyde D, Lochray F, Korol R et al (2012) Spine stereotactic body radiotherapy utilizing cone-beam CT image-guidance with a robotic couch: intrafraction motion analysis accounting for all six degrees of freedom. Int J Radiat Oncol Biol Phys 82(3):e555-562. https://doi.org/10.1016/j.ijrobp.2011.06.1980
doi: 10.1016/j.ijrobp.2011.06.1980 pubmed: 22284042
Sangha A, Korol R, Sahgal A (2013) Stereotactic body radiotherapy for the treatment of spinal metastases: an overview of the University of Toronto, Sunnybrook Health Sciences Odette Cancer Centre. Technique J Med Imaging Radiat Sci 44(3):126–133. https://doi.org/10.1016/j.jmir.2013.04.002
doi: 10.1016/j.jmir.2013.04.002 pubmed: 31052036
Tseng C-L, Soliman H, Myrehaug S et al (2018) Imaging-based outcomes for 24 Gy in 2 daily fractions for patients with de novo spinal metastases treated with spine stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 102(3):499–507. https://doi.org/10.1016/j.ijrobp.2018.06.047
doi: 10.1016/j.ijrobp.2018.06.047 pubmed: 30003994
Bodo S, Campagne C, Thin TH et al (2019) Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. J Clin Invest 129(2):786–801. https://doi.org/10.1172/JCI97631
doi: 10.1172/JCI97631 pubmed: 30480549 pmcid: 6355243
Marciscano AE, Haimovitz-Friedman A, Lee P et al (2019) Immunomodulatory effects of stereotactic body radiation therapy: preclinical insights and clinical opportunities. Int J Radiat Oncol Biol Phys S0360–3016(19):30290–30291. https://doi.org/10.1016/j.ijrobp.2019.02.046
doi: 10.1016/j.ijrobp.2019.02.046
Gerszten PC, Mendel E, Yamada Y (2009) Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine 34(22S):S78. https://doi.org/10.1097/BRS.0b013e3181b8b6f5
doi: 10.1097/BRS.0b013e3181b8b6f5 pubmed: 19829280
Sandhu N, Benson KRK, Kumar KA et al (2020) Local control and toxicity outcomes of stereotactic radiosurgery for spinal metastases of gastrointestinal origin. J Neurosurg Spine 1(aop):1–8. https://doi.org/10.3171/2020.1.SPINE191260
doi: 10.3171/2020.1.SPINE191260
Thibault I, Chang EL, Sheehan J et al (2015) Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol 16(16):e595-603. https://doi.org/10.1016/S1470-2045(15)00166-7
doi: 10.1016/S1470-2045(15)00166-7 pubmed: 26678212
Thompson R, Cheung P, Chu W et al (2020) Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: dose and site of metastases matter. Radiother Oncol 142:236–245. https://doi.org/10.1016/j.radonc.2019.08.018
doi: 10.1016/j.radonc.2019.08.018 pubmed: 31543287
Leeman JE, Bilsky M, Laufer I et al (2016) Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. J Neurosurg Spine 25(1):52–58. https://doi.org/10.3171/2015.11.SPINE151059
doi: 10.3171/2015.11.SPINE151059 pubmed: 26943256 pmcid: 5551386
Laufer I, Rubin DG, Lis E et al (2013) The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 18(6):744–751. https://doi.org/10.1634/theoncologist.2012-0293
doi: 10.1634/theoncologist.2012-0293 pubmed: 23709750 pmcid: 4063402
Kim JM, Miller JA, Kotecha R et al (2019) Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro Oncol 21(5):659–668. https://doi.org/10.1093/neuonc/noz006
doi: 10.1093/neuonc/noz006 pubmed: 30726965 pmcid: 6502492
Parsai S, Miller JA, Juloori A et al (2019) Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. J Neurosurg 132(2):503–511. https://doi.org/10.3171/2018.10.JNS182340
doi: 10.3171/2018.10.JNS182340 pubmed: 30738402
Carmichael J, Degraff WG, Gamson J et al (1989) Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 25(3):527–534. https://doi.org/10.1016/0277-5379(89)90266-6
doi: 10.1016/0277-5379(89)90266-6 pubmed: 2539297
Balasubramanian SK, Sharma M, Venur VA et al (2020) Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Neuro Oncol 22(2):267–277. https://doi.org/10.1093/neuonc/noz155
doi: 10.1093/neuonc/noz155 pubmed: 31648302
Miller JA, Kotecha R, Ahluwalia MS et al (2017) The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases. Pract Radiat Oncol 7(4):e263–e273. https://doi.org/10.1016/j.prro.2017.01.001
doi: 10.1016/j.prro.2017.01.001 pubmed: 28254368
Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659. https://doi.org/10.1001/jamaoncol.2020.0147
doi: 10.1001/jamaoncol.2020.0147 pubmed: 32215577 pmcid: 7225913
Arcangeli G, Micheli A, Arcangeli G et al (1989) The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol 14(2):95–101. https://doi.org/10.1016/0167-8140(89)90053-4
doi: 10.1016/0167-8140(89)90053-4 pubmed: 2469105
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453. https://doi.org/10.1200/JCO.2017.75.4853
doi: 10.1200/JCO.2017.75.4853 pubmed: 29240541
Cox BW, Spratt DE, Lovelock M et al (2012) International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83(5):e597-605. https://doi.org/10.1016/j.ijrobp.2012.03.009
doi: 10.1016/j.ijrobp.2012.03.009 pubmed: 22608954
Redmond KJ, Lo SS, Fisher C, Sahgal A (2016) Postoperative stereotactic body radiation therapy (SBRT) for spine metastases: a critical review to guide practice. Int J Radiat Oncol Biol Phys 95(5):1414–1428. https://doi.org/10.1016/j.ijrobp.2016.03.027
doi: 10.1016/j.ijrobp.2016.03.027 pubmed: 27479724
Dunne EM, Sahgal A, Lo SS et al (2020) International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT). Radiother Oncol 145:21–29. https://doi.org/10.1016/j.radonc.2019.11.026
doi: 10.1016/j.radonc.2019.11.026 pubmed: 31874346
Sahgal A, Weinberg V, Ma L et al (2013) Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 85(2):341–347. https://doi.org/10.1016/j.ijrobp.2012.05.007
doi: 10.1016/j.ijrobp.2012.05.007 pubmed: 22713832
Sahgal A, Chang JH, Ma L et al (2019) Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys S0360–3016(19):33862–33863. https://doi.org/10.1016/j.ijrobp.2019.09.038
doi: 10.1016/j.ijrobp.2019.09.038
Fisher CG, Schouten R, Versteeg AL et al (2014) Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases. Radiat Oncol 9:69. https://doi.org/10.1186/1748-717X-9-69
doi: 10.1186/1748-717X-9-69 pubmed: 24594004 pmcid: 3995991
Bilsky MH, Laufer I, Fourney DR et al (2010) Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine 13(3):324–328. https://doi.org/10.3171/2010.3.SPINE09459
doi: 10.3171/2010.3.SPINE09459 pubmed: 20809724
Jabehdar Maralani P, Winger K, Symons S et al (2018) Incidence and time of onset of osseous pseudoprogression in patients with metastatic spine disease from renal cell or prostate carcinoma after treatment with stereotactic body radiation therapy. Neurosurgery 84(3):647–654. https://doi.org/10.1093/neuros/nyy075
doi: 10.1093/neuros/nyy075
Ghia AJ, Guha-Thakurta N, Hess K et al (2018) Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously unirradiated metastatic epidural spinal cord compression. Int J Radiat Oncol Biol Phys 102(5):1481–1488. https://doi.org/10.1016/j.ijrobp.2018.07.2023
doi: 10.1016/j.ijrobp.2018.07.2023 pubmed: 30099131
Chang EL, Shiu AS, Mendel E et al (2007) Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 7(2):151–160. https://doi.org/10.3171/SPI-07/08/151
doi: 10.3171/SPI-07/08/151 pubmed: 17688054
Chan MW, Thibault I, Atenafu EG et al (2016) Patterns of epidural progression following postoperative spine stereotactic body radiotherapy: implications for clinical target volume delineation. J Neurosurg Spine 24(4):652–659. https://doi.org/10.3171/2015.6.SPINE15294
doi: 10.3171/2015.6.SPINE15294 pubmed: 26682603
Thibault I, Campbell M, Tseng C-L et al (2015) Salvage stereotactic body radiotherapy (SBRT) following in-field failure of initial SBRT for spinal metastases. Int J Radiat Oncol Biol Phys 93(2):353–360. https://doi.org/10.1016/j.ijrobp.2015.03.029
doi: 10.1016/j.ijrobp.2015.03.029 pubmed: 26383680
Laufer I, Iorgulescu JB, Chapman T et al (2013) Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 18(3):207–214. https://doi.org/10.3171/2012.11.SPINE12111
doi: 10.3171/2012.11.SPINE12111 pubmed: 23339593 pmcid: 5737630
Jakubovic R, Ruschin M, Tseng C-L, Pejović-Milić A, Sahgal A, Yang VXD (2019) Surgical resection with radiation treatment planning of spinal tumors. Neurosurgery 84(6):1242–1250. https://doi.org/10.1093/neuros/nyy176
doi: 10.1093/neuros/nyy176 pubmed: 29796646
Massicotte E, Foote M, Reddy R, Sahgal A (2012) Minimal access spine surgery (MASS) for decompression and stabilization performed as an out-patient procedure for metastatic spinal tumours followed by spine stereotactic body radiotherapy (SBRT): first report of technique and preliminary outcomes. Technol Cancer Res Treat 11(1):15–25. https://doi.org/10.7785/tcrt.2012.500230
doi: 10.7785/tcrt.2012.500230 pubmed: 22181327
Sahgal A, Myrehaug S, Dennis K et al (2017) A randomized phase II/III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases (NCT02512965). J Clin Oncol 35(15):TPS10129. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS10129
doi: 10.1200/JCO.2017.35.15_suppl.TPS10129
Sahgal A, Myrehaug S, Siva S, et al (2020) CCTG SC.24/TROG 17.06: a randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases. Presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting Abstract #: LBA 2. Published online 2020.
Fehlings MG, Nater A, Tetreault L et al (2016) Survival and clinical outcomes in surgically treated patients with metastatic epidural spinal cord compression: results of the prospective multicenter AOSpine study. J Clin Oncol 34(3):268–276. https://doi.org/10.1200/JCO.2015.61.9338
doi: 10.1200/JCO.2015.61.9338 pubmed: 26598751
Yamada Y, Bilsky MH, Lovelock DM et al (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71(2):484–490. https://doi.org/10.1016/j.ijrobp.2007.11.046
doi: 10.1016/j.ijrobp.2007.11.046 pubmed: 18234445
Rose PS, Laufer I, Boland PJ et al (2009) Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27(30):5075–5079. https://doi.org/10.1200/JCO.2008.19.3508
doi: 10.1200/JCO.2008.19.3508 pubmed: 19738130 pmcid: 3664037
Sahgal A, Atenafu EG, Chao S et al (2013) Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol 31(27):3426–3431. https://doi.org/10.1200/JCO.2013.50.1411
doi: 10.1200/JCO.2013.50.1411 pubmed: 23960179 pmcid: 6076012
Al-Omair A, Masucci L, Masson-Cote L et al (2013) Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy. Neuro-Oncol 15(10):1413–1419. https://doi.org/10.1093/neuonc/not101
doi: 10.1093/neuonc/not101 pubmed: 24057886 pmcid: 3779044
Alghamdi M, Sahgal A, Soliman H et al (2019) Postoperative stereotactic body radiotherapy for spinal metastases and the impact of epidural disease grade. Neurosurgery 85(6):E1111–E1118. https://doi.org/10.1093/neuros/nyz349
doi: 10.1093/neuros/nyz349 pubmed: 31506671
Bernard V, Bishop AJ, Allen PK et al (2017) Heterogeneity in treatment response of spine metastases to spine stereotactic radiosurgery within “Radiosensitive” subtypes. Int J Radiat Oncol Biol Phys 99(5):1207–1215. https://doi.org/10.1016/j.ijrobp.2017.08.028
doi: 10.1016/j.ijrobp.2017.08.028 pubmed: 29029886
Myrehaug S, Sahgal A, Hayashi M et al (2017) Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. J Neurosurg Spine 27(4):428–435. https://doi.org/10.3171/2017.2.SPINE16976
doi: 10.3171/2017.2.SPINE16976 pubmed: 28708043

Auteurs

K Liang Zeng (KL)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Arjun Sahgal (A)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Zain A Husain (ZA)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Sten Myrehaug (S)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Chia-Lin Tseng (CL)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Jay Detsky (J)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Arman Sarfehnia (A)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Mark Ruschin (M)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Mikki Campbell (M)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Monica Foster (M)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada.

Sunit Das (S)

Division of Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

Nir Lipsman (N)

Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Georg A Bjarnason (GA)

Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Eshetu G Atenafu (EG)

Department of Biostatistics, University Health Network, University of Toronto, Toronto, ON, Canada.

Pejman Jabehdar Maralani (PJ)

Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Hany Soliman (H)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada. hany.soliman@sunnybrook.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH